[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644918":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":10,"responsibleParty":28,"collaborators":10,"id":30,"slug":10,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":56,"leadSponsor":58,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Overall mCRPC Cohort",null,"Adult patients with a diagnosis of mCRPC and evidence of prior treatment with ≥1 ARPI, ≥1 taxane, and 177Lu-PSMA-617 in PRECISION.",{"label":13,"type":10,"description":14,"interventionNames":10},"mCRPC Progression Subgroup","A subgroup of the Overall mCRPC Cohort. Patients with evidence of progression on or after 177Lu-PSMA-617 treatment.",{"label":16,"type":10,"description":17,"interventionNames":10},"≥1 Subsequent Systemic Therapy Subgroup","A subgroup of the Overall mCRPC Cohort. Patients who initiate ≥1 post-index systemic therapy.",[19],{"name":20,"affiliation":20,"role":21},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[23,27],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":20,"role":24,"phone":10,"phoneExt":10,"email":10},{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100644918",false,"NCT07677267","A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan","Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan","Inclusion criteria:\n\n* Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.\n* Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.\n* Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.\n* Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.\n* Age ≥18 years at index.\n\nExclusion criteria:\n\n• None.","MALE","18 Years","115 Years",{"count":40,"type":41},1067,"ESTIMATED","OBSERVATIONAL","The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.",[45],"Prostatic Neoplasms, Castration-Resistant",[47,48,49],"Metastatic Castration-Resistant Prostate Cancer","Androgen Pathway Modulation-Resistant","APMR","NOT_YET_RECRUITING","2026-06-24",{"date":53,"type":54},"2026-06-30","ACTUAL",{"date":53,"type":41},{"date":57,"type":41},"2026-11-30",{"name":20,"class":6}]